# Joerg Herrmann

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/joerg-herrmann/

## Facts

| Field | Value |
| --- | --- |
| Citations | 18,386 |
| Field | Chemotherapy-induced cardiotoxicity and mitigation |
| h-index | 64 |
| i10-index | 165 |
| Last Known Institution | Mayo Clinic |
| OpenAlex ID | https://openalex.org/A5102760225 |
| ORCID iD | 0000-0001-6675-4559 |
| Works | 366 |

## Researcher papers

Showing 12 of 15.

- [2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)](https://scholariq.org/papers/2022-esc-guidelines-on-cardio-oncology-developed-in-collaboration-with-the-2/)
- [Baseline Cardiovascular Risk Assessment in Cancer Patients Scheduled to Receive Cardiotoxic Cancer Therapies: A Position Statement and New Risk Assessment Tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in Collaboration with the International Cardio-Oncology Society](https://scholariq.org/papers/baseline-cardiovascular-risk-assessment-in-cancer-patients-scheduled-to-receive/)
- [Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia](https://scholariq.org/papers/adverse-cardiac-effects-of-cancer-therapies-cardiotoxicity-and-arrhythmia/)
- [Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement](https://scholariq.org/papers/defining-cardiovascular-toxicities-of-cancer-therapies-an-international-cardio/)
- [5-fluorouracil and cardiotoxicity: a review](https://scholariq.org/papers/5-fluorouracil-and-cardiotoxicity-a-review/)
- [Evaluation and Management of Patients With Heart Disease and Cancer: Cardio-Oncology](https://scholariq.org/papers/evaluation-and-management-of-patients-with-heart-disease-and-cancer-cardio/)
- [Glycolytic Stimulation Is Not a Requirement for M2 Macrophage Differentiation](https://scholariq.org/papers/glycolytic-stimulation-is-not-a-requirement-for-m2-macrophage-differentiation/)
- [Myocardial bridging](https://scholariq.org/papers/myocardial-bridging/)
- [Interferon Gamma Induces Reversible Metabolic Reprogramming of M1 Macrophages to Sustain Cell Viability and Pro-Inflammatory Activity](https://scholariq.org/papers/interferon-gamma-induces-reversible-metabolic-reprogramming-of-m1-macrophages-to/)
- [Vascular Toxicities of Cancer Therapies](https://scholariq.org/papers/vascular-toxicities-of-cancer-therapies/)
- [Cardiovascular Health of Patients With Cancer and Cancer Survivors](https://scholariq.org/papers/cardiovascular-health-of-patients-with-cancer-and-cancer-survivors/)
- [Programmed cell death protein 1 inhibitor treatment is associated with acute kidney injury and hypocalcemia: meta-analysis](https://scholariq.org/papers/programmed-cell-death-protein-1-inhibitor-treatment-is-associated-with-acute/)

## Researcher topics

- [Chemotherapy-induced cardiotoxicity and mitigation](https://scholariq.org/topics/chemotherapy-induced-cardiotoxicity-and-mitigation/)
- [Cardiac Imaging and Diagnostics](https://scholariq.org/topics/cardiac-imaging-and-diagnostics/)
- [Cancer Treatment and Pharmacology](https://scholariq.org/topics/cancer-treatment-and-pharmacology/)
- [Coronary Interventions and Diagnostics](https://scholariq.org/topics/coronary-interventions-and-diagnostics/)
- [Acute Myocardial Infarction Research](https://scholariq.org/topics/acute-myocardial-infarction-research/)

## Researcher university

- [Mayo Clinic](https://scholariq.org/institutions/mayo-clinic/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.